Albany Molecular Research (Albany Molecular Research) COGS-to-Revenue : 0.76 (As of Jun. 2017)

View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research COGS-to-Revenue?

Albany Molecular Research's Cost of Goods Sold for the three months ended in Jun. 2017 was $131.7 Mil. Its Revenue for the three months ended in Jun. 2017 was $172.9 Mil.

Albany Molecular Research's COGS to Revenue for the three months ended in Jun. 2017 was 0.76.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Albany Molecular Research's Gross Margin % for the three months ended in Jun. 2017 was 23.83%.

Albany Molecular Research COGS-to-Revenue Historical Data

The historical data trend for Albany Molecular Research's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research COGS-to-Revenue Chart

Albany Molecular Research Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

COGS-to-Revenue

Get a 7-Day Free Trial

0.74

0.70

0.76

0.73

0.77

Albany Molecular Research Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
COGS-to-Revenue	Get a 7-Day Free Trial															0.68	0.81	0.80	0.75	0.76

Albany Molecular Research COGS-to-Revenue Calculation

Albany Molecular Research's COGS to Revenue for the fiscal year that ended in Dec. 2016 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	437.649	/	570.45
	=	0.77

Albany Molecular Research's COGS to Revenue for the quarter that ended in Jun. 2017 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	131.715	/	172.932
	=	0.76

Albany Molecular Research (NAS:AMRI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Albany Molecular Research's Gross Margin % for the three months ended in Jun. 2017 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	131.715 / 172.932
	=	23.83 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Albany Molecular Research COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Albany Molecular Research (Albany Molecular Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.amriglobal.com

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Executives

Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin	officer: SVP, Treasurer & CFO	26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming	director	C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth	director, officer: President and CEO	236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson	officer: SVP, Secretary & Gen Counsel	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther	officer: Senior VP, Discovery Services	21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost	officer: Chief Financial Officer	21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek	officer: Chief Financial Officer	ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines